Work

Rituximab Added to CODOX-M/IVAC has No Clear Benefit Compared to CODOX-M/IVAC alone in Adult Patients with Burkitt Lymphoma.

Year: 2009

Type: article

Study design: Observational Study

Source: Blood

DOI: 10.1182/blood.v114.22.1667.1667

Authors: Barnes A. Barnes, Ann S. LaCasce, Yang Feng, Christiana Toomey, Donna Neuberg, Ephraim P. Hochberg, Jeremy S. Abramson

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2481651118

FWCI: 1.052

Cites:

Cited by: 8

Related to: 10